Betahistine: Indications, Dosage, and Contraindications
Primary Indication
Betahistine is historically used for Ménière's disease and peripheral vestibular vertigo, but the highest quality evidence shows it is NOT more effective than placebo for reducing vertigo attacks. 1
Evidence Quality and Clinical Reality
The 2020 American Academy of Otolaryngology-Head and Neck Surgery clinical practice guideline explicitly states they are "unable to make a definitive statement on use of betahistine to control MD symptoms" based on the well-designed BEMED trial 1. This landmark double-blind RCT found no significant difference between placebo, low-dose (48 mg/day), or high-dose (144 mg/day) betahistine in reducing vertigo attacks over 9 months 1, 2.
Despite lack of proven efficacy for Ménière's disease, betahistine continues to be prescribed for:
- Ménière's disease symptoms (vertigo, tinnitus, aural fullness)
- Peripheral vestibular vertigo of various etiologies
- Residual dizziness after benign paroxysmal positional vertigo (BPPV) treatment
- Uncompensated unilateral vestibulopathy 3, 4, 5, 6
Dosage
Standard dosing ranges from 48-144 mg daily, divided into 2-3 doses:
- Low dose: 48 mg/day (24 mg twice daily) 1, 2
- High dose: 144 mg/day (48 mg three times daily) 1, 2
- Alternative regimen: 16 mg twice daily (32 mg/day total) 6
- Japanese standard: 36 mg/day, with escalation to 72 mg/day for intractable cases 4
Duration of Treatment
- Most studies evaluated 2-12 weeks of treatment 1
- The BEMED trial used 9 months 1, 2
- Clinical approach: Reassess frequently for symptom improvement or medication intolerance; consider titrating down or stopping once symptoms subside 1
- No clear evidence defines optimal treatment duration 1
Contraindications
Absolute Contraindications
Betahistine must be avoided in patients with pheochromocytoma 1
Use with Caution
Exercise caution in patients with:
Additional FDA-Listed Contraindications (for histamine products)
- Hypotension
- Severe hypertension
- Severe cardiac, pulmonary, or renal disease 7
Safety Profile
Betahistine is generally well-tolerated with rare serious adverse effects. Common side effects include 1:
- Headache
- Balance disorder
- Nausea
- Nasopharyngitis
- Feeling hot
- Eye irritation
- Palpitations
- Upper gastrointestinal symptoms
Clinical Decision Algorithm
Given the evidence:
For Ménière's disease: Inform patients that betahistine has not proven superior to placebo in high-quality trials, but has an excellent safety profile. If prescribed, use 48-144 mg/day divided into 2-3 doses 1, 2
For other peripheral vertigo: Consider trial of 48 mg/day for 3 months, though evidence quality is lower than for Ménière's disease 5, 6
Screen for contraindications: Specifically ask about pheochromocytoma, asthma, and peptic ulcer history before prescribing 1
Monitoring: Reassess at clinically appropriate intervals (typically 2-4 weeks initially) for symptom response and adverse effects 1
Discontinuation: If no improvement after 6-12 weeks, consider stopping given lack of proven efficacy 1
Important Caveat
The natural history of Ménière's disease includes spontaneous fluctuation and remission. The BEMED trial showed significant decline in vertigo attacks across ALL groups (including placebo) over 9 months, making it difficult to attribute improvement to medication versus natural disease course 1, 2.